Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €433.00 EUR
Change Today -13.11 / -2.94%
Volume 4.0
RGO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 1:24 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for regeneron pharmaceuticals (RGO)

Year over year, Regeneron Pharmaceuticals, Inc. has been seen their bottom line shrink from $424.4M USD to $348.1M USD despite an increase in revenues from $2.1B USD to $2.8B USD. An increase in the percentage of sales devoted to cost of goods sold from 48.24% to 52.36% was a key component in the falling bottom line in the face of rising revenues.
Currency in
Millions of US Dollars
As of:Dec 31
2011
Reclassified
Dec 31
2012
Dec 31
2013
Dec 31
2014
4 Year
Trend
Revenues445.81,378.52,104.72,819.6
TOTAL REVENUES445.81,378.52,104.72,819.6
Cost of Goods Sold533.7710.01,015.31,476.4
GROSS PROFIT-87.9668.51,089.41,343.2
Selling General & Admin Expenses, Total117.3210.8329.4504.8
OTHER OPERATING EXPENSES, TOTAL117.3210.8329.4504.8
OPERATING INCOME-205.2457.7760.0838.4
Interest Expense-21.3-45.3-46.4-37.4
Interest and Investment Income3.52.01.77.0
NET INTEREST EXPENSE-17.7-43.3-44.8-30.4
EBT, EXCLUDING UNUSUAL ITEMS-222.9414.4715.3808.0
Gain (Loss) on Sale of Investments-----1.91.2
Other Unusual Items, Total-------33.5
Other Unusual Items-------33.5
EBT, INCLUDING UNUSUAL ITEMS-222.9414.4713.4775.7
Income Tax Expense-1.1-335.8289.0427.7
Earnings from Continuing Operations-221.8750.3424.4348.1
NET INCOME-221.8750.3424.4348.1
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-221.8750.3424.4348.1
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-221.8750.3424.4348.1
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGO:GR €433.00 EUR -13.11

RGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $117.58 USD -2.70
Incyte Corp $101.43 USD -5.91
Pharmacyclics Inc $256.69 USD +0.10
UCB SA €69.23 EUR +0.21
Vertex Pharmaceuticals Inc $127.55 USD -5.65
View Industry Companies
 

Industry Analysis

RGO

Industry Average

Valuation RGO Industry Range
Price/Earnings 100.0x
Price/Sales 17.3x
Price/Book 19.2x
Price/Cash Flow 139.7x
TEV/Sales 16.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.